Literature DB >> 25164540

Maternal outcomes in pregnancies affected by varicella zoster virus infections: population-based study on 7.7 million pregnancy admissions.

Hui Jue Zhang1, Valerie Patenaude, Haim A Abenhaim.   

Abstract

AIM: Previous estimates of the incidence of varicella zoster virus (VZV) pneumonia and maternal death associated with VZV infection among the pregnant population have varied considerably and been based predominantly on reports from case series. We sought to measure the incidence of VZV-related morbidity and mortality to provide more representative population estimates.
METHODS: We carried out a large cohort study on all births using the United States Healthcare Cost and Utilization Project-Nationwide Inpatient Sample database between 2003 and 2010. Descriptive statistics were used to measure baseline characteristics and outcomes of women with VZV infection. Multivariate logistic regression analyses were used to identify risk factors for the development of VZV-related morbidity and mortality.
RESULTS: We identified 935 patients admitted for VZV infection among 7.7 million pregnancy admissions, representing an incidence of 1.21 cases/10 000 pregnancies (95% confidence interval [CI], 1.13-1.29). The incidence of VZV pneumonia was 2.5% (95% CI, 1.6-3.7). No maternal deaths were recorded during the 8-year study period. There were no significant risk factors identified for those who developed VZV pneumonia compared to those who had an uncomplicated VZV infection during pregnancy.
CONCLUSION: The incidence of VZV pneumonia and VZV infection associated with maternal death is significantly lower than previously estimated and may reflect better immunization and earlier interventions.
© 2014 The Authors. Journal of Obstetrics and Gynaecology Research © 2014 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  mortality; pneumonia; pregnancy; varicella zoster virus

Mesh:

Year:  2014        PMID: 25164540     DOI: 10.1111/jog.12479

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  6 in total

1.  Clinical benefits of routine varicella vaccination for adults.

Authors:  Cinzia Germinario; Maria Serena Gallone; Maria Giovanna Cappelli; Silvio Tafuri
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Prolonged activation of innate antiviral gene signature after childbirth is determined by IFNL3 genotype.

Authors:  Aryn A Price; Dana Tedesco; Mona R Prasad; Kimberly A Workowski; Christopher M Walker; Mehul S Suthar; Jonathan R Honegger; Arash Grakoui
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

3.  Has VZV epidemiology changed in Italy? Results of a seroprevalence study.

Authors:  Antonella De Donno; Parvanè Kuhdari; Marcello Guido; Maria Cristina Rota; Antonino Bella; Giordana Brignole; Silvia Lupi; Adele Idolo; Armando Stefanati; Martina Del Manso; Giovanni Gabutti
Journal:  Hum Vaccin Immunother       Date:  2016-12-27       Impact factor: 3.452

4.  Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: Varicella outcomes and safety results from a large, open-label, expanded-access program.

Authors:  Myron J Levin; Jennifer M Duchon; Geeta K Swamy; Anne A Gershon
Journal:  PLoS One       Date:  2019-07-03       Impact factor: 3.240

Review 5.  Management of chickenpox in pregnant women: an Italian perspective.

Authors:  Serena Parente; Nicola Schiano Moriello; Alberto Enrico Maraolo; Grazia Tosone
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-25       Impact factor: 3.267

6.  First trimester COVID-19 and the risk of major congenital malformations-International Registry of Coronavirus Exposure in Pregnancy.

Authors:  Sonia Hernández-Díaz; Louisa H Smith; Diego F Wyszynski; Sonja A Rasmussen
Journal:  Birth Defects Res       Date:  2022-08-05       Impact factor: 2.661

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.